Antineoplastons (generic name)
- Auto Immune Conditions
- Bladder & Kidney Health
- Brain & Nervous System
- Care Transitions
- Dental Health
- Emotional Health
- Eye Health
- Falls Prevention
- Financial Planning
- General Safety
- Health Care Basics
- Healthy Living
- Hearing Loss
- Heart Health
- High Blood Pressure
- Life Transitions
- Lung Health
- Men's Health
- Nutrition & Weight Management
- Pain Management
- Preventive Health
- Sexual Health
- Stomach & Digestive Health
- Stress & Anxiety
- Women's Health
Interactions with Drugs
Limited information is available about interactions with antineoplastons. Agents with adverse effects similar to antineoplastons may have additive effects, such as lowering blood potassium or glucose levels, or causing liver abnormalities. It is not known if antineoplastons add to the effects of chemotherapeutic drugs.
Interactions with Herbs and Supplements
Limited information is available about interactions with antineoplastons. Agents with adverse effects similar to antineoplastons may have additive effects, such as lowering blood potassium or glucose levels, or causing liver abnormalities.
This information is based on a professional level monograph edited and peer-reviewed by contributors to the Natural Standard Research Collaboration (www.naturalstandard.com): Ethan Basch, MD, MSc, MPhil (Memorial Sloan Kettering Cancer Center); Cynthia Dacey, PharmD (Northeastern University); Sadaf Hashmi, MD, MPh (Johns Hopkins School of Hygiene and Public Health); Melissa Leck, PharmD (Massachusetts College of Pharmacy); Catherine Ulbricht, PharmD (Massachusetts General Hospital).
BibliographyDISCLAIMER: Natural Standard developed the above evidence-based information based on a thorough systematic review of the available scientific articles. For comprehensive information about alternative and complementary therapies on the professional level, go to www.naturalstandard.com. Selected references are listed below.
Badria F, Mabed M, Khafagy W, et al. Potential utility of antineoplaston A-10 levels in breast cancer. Cancer Letters 2000;157(1):67-70.
Badria F, Mabed M, El Awadi M, et al. Immune modulatory potentials of antineoplaston A-10 in breast cancer patients. Cancer Lett. 8-31-2000;157(1):57-63.
Buckner JC, Malkin MG, Reed E, et al. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc 1999;74(2):137-145.
Burzynski SR, Kubove E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years' follow-up. Drugs Exp Clin Res 1987;13 Suppl 1:1-11.
Burzynski SR, Kubove E, Burzynski B. Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1. Drugs Exp Clin Res 1990;16(7):361-369.
Burzynski SR. Potential of antineoplastons in diseases of old age. Drugs Aging 1995;7(3):157-167.
Green S. 'Antineoplastons'. An unproved cancer therapy. JAMA 6-3-1992;267(21):2924-2928.
Juszkiewicz M, Chodkowska A, Burzynski SR, et al. The influence of antineoplaston A5 on particular subtypes of central dopaminergic receptors. Drugs Exp Clin Res 1995;21(4):153-156.
Kumabe T, Tsuda H, Uchida M, Ogoh Y, et al. Antineoplaston treatment for advanced hepatocellular carcinoma. Oncol Rep 1998;5(6):1363-1367.
Liau MC, Szopa M, Burzynski B, et al. Quantitative assay of plasma and urinary peptides as an aid for the evaluation of cancer patients undergoing antineoplaston therapy. Drugs Exp Clin Res 1987;13 Suppl 1:61-70.
Soltysiak-Pawluczuk D, Burzynski SR. Cellular accumulation of antineoplaston AS21 in human hepatoma cells. Cancer Lett. 1-6-1995;88(1):107-112.
Sugita Y, Tsuda H, Maruiwa H, et al. The effect of antineoplaston, a new antitumor agent on malignant brain tumors. Kurume Med J 1995;42(3):133-140.
Tsuda H, Sata M, Saitsu H, et al. Antineoplaston AS2-1 for maintenance therapy in liver cancer. Oncology Reports 1997;4:1213-1216.
Tsuda H, Iemura A, Sata M, et al. Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma. Kurume Med J 1996;43(2):137-147.
Tsuda H, Sata M, Kumabe T, et al. Quick response of advanced cancer to chemoradiation therapy with antineoplastons. Oncol Rep. 1998;5(3):597-600.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.